Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease
David E. Griffith(National Jewish Health), Kevin Winthrop(Oregon Health & Science University), Kozo Morimoto(Japan Anti Tuberculosis Association), Jakko van Ingen(Radboud University Nijmegen), Doreen Addrizzo‐Harris(Unknown), Rachel Thomson(The University of Queensland), Stephen K. Field(University of Calgary), Timothy R. Aksamit(Mayo Clinic), Wouter Hoefsloot(Radboud University Nijmegen), Richard J. Wallace(The University of Texas at Tyler), Chris Coulter(Queensland Health), Kevin C. Mange(Insmed (United States)), Dayton W. Yuen(Insmed (United States)), Barbara A. Brown‐Elliott(The University of Texas Health Science Center at Tyler), Monika Ciesielska(Insmed (United States)), Patrick A. Flume(Medical University of South Carolina)
Cited by 52
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
|CHEST Journal|2006|1.2k
Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery
|CHEST Journal|2013|901
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
|European Respiratory Journal|2020|876